TOP TEN perturbations for 38868_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38868_at
Selected probe(set): 207674_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38868_at (207674_at) across 6674 perturbations tested by GENEVESTIGATOR:

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):-5.109629
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):5.0753984
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-5.001356
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.781535
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.7804813
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.7564926
Number of Samples:232 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.675085
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.4556503
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

ALL study 2 (33d) / ALL study 2 (0d)

Relative Expression (log2-ratio):4.454479
Number of Samples:58 / 129
Experimental ALL study 2 (33d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 33 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.39649
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.